- Home
- TNXP vs NCRA Comparison
TNXP vs NCRA Comparison
Compare TNXP & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- NCRA
- Stock Information
- Founded
- TNXP 2007
- NCRA 2002
- Country
- TNXP United States
- NCRA Taiwan
- Employees
- TNXP N/A
- NCRA N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- NCRA Farming/Seeds/Milling
- Sector
- TNXP Health Care
- NCRA Consumer Staples
- Exchange
- TNXP Nasdaq
- NCRA Nasdaq
- Market Cap
- TNXP 272.0M
- NCRA 14.8M
- IPO Year
- TNXP N/A
- NCRA N/A
- Fundamental
- Price
- TNXP $44.20
- NCRA $1.03
- Analyst Decision
- TNXP Strong Buy
- NCRA
- Analyst Count
- TNXP 2
- NCRA 0
- Target Price
- TNXP $585.00
- NCRA N/A
- AVG Volume (30 Days)
- TNXP 728.4K
- NCRA 34.5K
- Earning Date
- TNXP 08-15-2025
- NCRA 08-13-2025
- Dividend Yield
- TNXP N/A
- NCRA N/A
- EPS Growth
- TNXP N/A
- NCRA N/A
- EPS
- TNXP N/A
- NCRA N/A
- Revenue
- TNXP $10,041,000.00
- NCRA $16,647,379.00
- Revenue This Year
- TNXP $22.87
- NCRA N/A
- Revenue Next Year
- TNXP $711.66
- NCRA N/A
- P/E Ratio
- TNXP N/A
- NCRA N/A
- Revenue Growth
- TNXP N/A
- NCRA N/A
- 52 Week Low
- TNXP $6.76
- NCRA $0.70
- 52 Week High
- TNXP $130.00
- NCRA $2.09
- Technical
- Relative Strength Index (RSI)
- TNXP 67.25
- NCRA 51.00
- Support Level
- TNXP $38.87
- NCRA $0.97
- Resistance Level
- TNXP $43.80
- NCRA $1.05
- Average True Range (ATR)
- TNXP 2.89
- NCRA 0.05
- MACD
- TNXP 0.63
- NCRA 0.00
- Stochastic Oscillator
- TNXP 77.52
- NCRA 80.00
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.